Correcting Hormone Imbalance with Detoxification
Toxic exposure begins in the earliest stages of life as the fetus is contaminated by poisons passing through the placenta. The average newborn in the U.S. has over 206 toxic chemicals present in her tiny body the day of birth. The toxic onslaught continues as poisons are passed from the mother to the newborn via the breast milk. The typical baby and her family are surrounded by poisoned air, food and water. Another major source of contamination is the infant vaccines that still contain Thimerosal, a neurologically-devastating derivative of Mercury used as a preservative in multi-dose vials of vaccines. More and more evidence suggests that Thimerosal is a major factor contributing to the current autism rate of 1/150 children.
This autism rate occurs only in the U.S., where the typical 2 y/o toddler has been inoculated with over thirty-five different vaccines, sometimes with as many as eight administered on the same day. The other common source of Mercury is dental Mercury amalgam. It is estimated that 90% of Americans have Mercury amalgam in their mouths. This carcinogenic, toxic heavy metal off-gasses continuously from the amalgam in the mouth and travels directly via nerve pathways to the brain and throughout the entire body.
|?Healthy? 34 y/o Male|
|CC: Fatigue, decrease memory and focus|
|20lb weight gain|
|Free T4||1.62||0.8 - 1.6 ng/dL||0.8 - 1.6 ng/dL|
|Free T3||2.35||4.0 - 4.5 pg/mL||4.0 - 4.5 pg/mL|
|DHEA-SO4||125||>350.0mcg/dL||> 450.0 mcg/dL|
|Estradiol||26||30.0 - 35.0 pg/mL||< 35.0 pg/mL|
|Progesterone||<0.3||0.8 - 1.4 ng/mL||0.8 - 1.4 ng/mL|
|Total Testosterone||231||30.0 - 35.0 ng/dL||> 500 ng/dL|
|The key points of these results are the optimal level of Free T4 with low conversion to Free T3.|
|Level of DHEA-SO4 is low and there is a toxic shift of DHEA sulfate metabolism to Estradiol, and away from Testosterone and Progesterone.|
Let?s examine symptoms related to a toxically impaired endocrine system. Hormones are messenger molecules that interact with receptors on the cell membranes to instruct the cell as to what to do. Common symptoms/diseases of deficient endocrine function include: Obesity, Diabetes, Hypercholesterolemia, Hyper or Hypo glandular function, Infertility, Fatigue, Chronic Fatigue, Fibromyalgia, Sexual dysfunction, Decreased libido, Impaired memory, Mood disorder, Sleep disturbance, Decreased cognitive function, Decreased cardiac function, Decrease muscle mass, Decreased bone mass, Osteopenia, Constipation, Cold hands/ cold feet, and more. In conventional allopathic medicine, a patient is told that the ?symptom? she is experiencing (such as one listed previously) is the ?problem?, and ?Oh, have I got a pharmaceutical drug for you!? Pharmaceutical drugs do not correct the problem of poisoned endocrine pathways.
|?Healthy? 53y/o Female|
|CC: 20lb weight gain, irregular periods, fatigue|
|Cold hands and feet, decreased memory|
|Free T4||0.8||0.8 - 1.6 ng/dL||0.8 - 1.6 ng/dL|
|Free T3||1.62||4.0 - 4.5 pg/mL||4.0 - 4.5 pg/mL|
|DHEA-SO4||177||>350.0mcg/dL||> 450.0 mcg/dL|
|Estradiol||25||30.0 - 35.0 pg/mL||< 35.0 pg/mL|
|Progesterone||0.33||0.8 - 1.4 ng/mL||0.8 - 1.4 ng/mL|
|Total Testosterone||43||30.0 - 35.0 ng/dL||> 500 ng/dL|
|The key points of these results are the optimal level of Free T4 with very low conversion to Free T3.|
|A low DHEA-SO4 level is present with a toxic shift of DHEA-SO4 metabolism to Testosterone away from Estradiol and Progesterone.|
Let?s examine some poisoned endocrine pathways and how these cause symptoms/diseases. Mercury and other toxic heavy metals are major offenders as mentioned previously. Mercury specifically competes with Magnesium and interferes with all Magnesium-dependent metabolic pathways such as production of energy from ATP and GTP which directly leads to lack of chemical energy. Every cell in the body requires chemical energy derived from ATP or GTP to function, heal and regenerate. If Mercury is present, this cannot occur and results in a long list of symptoms.
Specifically related to hormone production and regulation, Mercury and other toxins prevent the conversion of Free T4 (inactive) to Free T3 (active). The enzyme required for this conversion is the 5?-deiodinase enzyme. This enzyme is inactivated by Mercury, Arsenic, Cadmium and Lead. The conventional allopathic approach to thyroid assessment and treatment is based upon incorrect assumptions. The Thyroid Stimulating Hormone (TSH) test has become the allopathic Gold Standard Test for conventional thyroid function assessment. TSH is produced by the Pituitary gland in a negative feedback pathway in relationship to the Free T4 (inactive) level. The fallacy is that TSH production has nothing to do with the activity and production of Free T3 which is the active thyroid hormone. This is called Central Dysregulation, of which every poisoned person in America is a victim.
Every cell in the body requires Free T3 to function and regenerate. What are the symptoms of low Free T3? Obesity, Decreased muscle mass, Hypercholesterolemia, Hyperlipidemia, Decreased memory, Decreased cognitive function, Depression, Anxiety, Sleep disturbance, Constipation, Low Basal Body Temperature, Cold hands/cold feet, Dry skin, Hair loss, Brittle nails, Decreased cardiac function, and Slowed electrical conduction in nerves to list a few. These symptoms quickly resolve with bio-identical supplementation of Free T3 to optimal levels. Free T3 has a short half-life and should be taken twice a day, morning and 8-10 hours later. Lab levels can be rechecked every 4 weeks and blood should be drawn 2 hours after morning dose for a peak level. Optimal range for Free T3 is 4.0-4.5 according to the American Academy of Anti-Aging Medicine.
Incidentally, the Reference Ranges on lab reports are meaningless to the individual. Any practitioner can tell you the number of times these ?ranges? have been updated or revised. The Reference Range is determined by the most recent series of samples (with 2 standard deviations) from a ?dead and dying? patient population. These ranges are not Optimal Ranges based upon samples from an optimally healthy and functioning patient population. The American Academy of Anti-Aging Medicine has provided Optimal Ranges for various hormone tests at their seminars. The goal however, is for you to produce your own Free T3 and this is accomplished by effective detoxification using Results RNA? ACZ nano to quickly, safely and inexpensively remove the Mercury and other toxins from the body.
Another critical endocrine aspect is adrenal function. Toxins interfere with proper metabolic pathways involving Dehydroepiandrosterone (DHEA) and DHEA sulfate (the stable ester form). Dehydroepiandrosterone (DHEA) is a major steroidal hormone and precursor that has a broad range of biological effects in humans and other mammals. Together with its sulfate ester (DHEA-S), it is the most abundant steroid in humans. DHEA is produced by adrenal glands, fat cells and also synthesized in the brain. DHEA can be metabolized into other sex hormones, including Testosterone and Estrogens, and up to 150 individual metabolites. Studies have shown that after about age 35, DHEA-SO4 levels begin to decline. DHEA levels are now starting to fall at an earlier age and more rapidly due to the effects of toxins.
The following labs are typical results that I?ve seen in thousands of supposed ?healthy? people who were evaluated for symptoms such as ?feeling stupid, fat and tired.? These people had gone to practitioners who ran the conventional standard tests and told they were ?fine?. When these patients? hormone levels were brought to optimal levels and toxicity was reduced, their symptoms resolved.
It only makes sense that in order for our cells to function, heal and regenerate, we must reduce our toxic body burden by removing the toxins using ACZ nano; to kill the pathogens taking advantage of our compromised immune systems by using ACS 200, and to optimize our hormones levels.
1. Public Health Agency of Canada data www.PublicHealthAgencyofCanada.com
2. Seattle Post Intelligencer, March 22, 2001, ?We are walking, talking toxic waste sites, CDC survey finds?, Joan Lowy,Scripps Howard News Service
3. 1991 World Health Organization report -Dental amalgams constitute the major human exposure to mercury.
4. Environmental Working Group research. www.ewg.org.
5. Mercury reaches directly through nerves. Environmental Science and Technology. (33) Oct.99.
6. EPA Report, 2002
7. Schrauzer) Georg Thieme Verlag, Stuttgart- New York (1995).: c. Pendergrass, J.C. and Haley, B.E. Inhibition of Brain Tubulin- Guanosine 5-Triphosphate Interactions by Mercury: Similarity to Observations in Alzheimer?s Diseased Brain. In Metal Ions in Biological Systems V34, pp 461-478. Mercury and Its Effects on Environment and Biology, Chapter 16. Edited by H. Sigel and A. Sigel. Marcel Oekker, Inc. 270 Madison Ave., N.Y., N.Y. 10016 (1996).
8. Pendergrass, J. C, Haley, B.E., Vimy, M. 1., WinfiekJ, S.A. and Lorscheider, F.L. Mercury Vapor Inhalation Inhibits Binding of GTP to Tubulin in Rat Brain: Similarity to a Molecular Lesion in Alzheimer?s Disease Brain. Neurotoxicology 18(2), 315-324 (1997).
9. David, S., Shoemaker, M., and Haley, B. Abnormal Properties of Creatine kinase in Alzheimer?s Diseased Brain: Correlation of Reduced Enzyme Activity and Active Site Photolabeling with Aberrant Cytosol- Membrane Partitioning. Molecular Brain Research 54, 276-287 (1998).
10. Leong, CCW, Syed, N.I., and Lorscheider, F.L. Retrograde Degeneration of Neurite Membrane Structural Integrity and Formation of Neurofibillary Tangles at Nerve Growth Cones Following In Vitro Exposure to Mercury. NeuroReports 12 (4): 733-737, 2001.
11. Olivieri, G., Brack, Ch., Muller-Spahn, F? Stahelin, H.B., Herrmann, M., Renard, P; Brockhaus, M. and Hock, C. Mercury Induces Cell Cytotoxicity and Oxidative Stress and Increases b-amyloid Secretion and Tau Phosphorylation in SHSY5Y Neuroblastoma Cells. 3. Neurochemistry 74, 231-231, 2000.
12. Kingman, A., Albertini, T, and Brown, LJ. Mercury Concentrations in Urine and Whole-Blood Associated with Amalgam Exposure in a U.S. Military Population. 3, Dental Research 77(3) 461-71, 1998.
13. Chew, C. I_, Soh, G., Lee, A. S. and Yeoh, T. S. Long-term Dissolution of Mercury from a Non- Mercury-Releasing Amalgam. Clinical Preventive Dentistry 13(3): 5-7, May-June (1991).
14. Hahn, L.J., Kloiber, R., Vimy, M. J., Takahashi, Y. and Lorscheider, F.L. Dental ?Silver? Tooth Fillings: A Source of Mercury Exposure Revealed by Whole-Body Image Scan and Tissue Analysis. FASEB 3, 3, 2641-2646, 1989.
15. Hahn, L.3., Kloiber, R,, Leininger, R.W., Vimy, M. J., and Lorscheider, F.L Whole-body Imaging of the Distribution of Mercury Released from Dental Filling Into Monkey Tissues. FASEB F. 4, 3256-3260, 1990.
16. Hock, C, Drasch, G., Golombowskl, S., Muller-Span, F., Willerhausen-Zonnchen, B., Schwarz, P., Hock, U., Growdon, J.H., and Nitsch, R.M. Increased Blood Mercury Levels in Patients with Alzheimer?s Disease. 3. of Neural Transmission vl05(l) 59-68, 1998.
17. Frustaci, A., Magnavrta, N., Chimenti, C, Caldarulo, M., Sabbioni, E., Pletra, R., Cellini. C, Possati, G. F, and Maseri, A. Marked Elevation of Myocardial Trace Elements in Idiopathic Dilated Cardiomyopathy Compared With Secondary Dysfunction. J. of the American College Cardiology v33(6) 1578-1583, 1999,
18. Schubert, 3., Riley, E.I., and Tyler, S.A. Combined Effects in Toxicology-A Rapid Systemic Testing Procedure: Cadmium, Mercury and Lead. 3. of Toxicology and Environmental Health v4, 763-776,1978.
19. Wataha, J. C, Nakajima, H., Hanks, C. T., and Okabe, T. Correlation of Cytotoxicity with Element Release from Mercury and Gallium-based Dental Alloys in vitro. Den tal Materials 10(5) 298-303, Sept. (1994)
20. Harper?s illustrated Biochemistry, 27th edition, Ch.41 ?The Diversity of the Endocrine system?
21. Wolkowitz, O. M.; Kramer, J. H.; Reus, V. I. et al. (2003). ?DHEA treatment of Alzheimer?s disease: a randomized, double-blind, placebo-controlled study?. Neurology 60 (7): 1071?6. PMID 12682308.
22. Wolkowitz, O. M.; Reus, V. I.; Keebler, A. et al. (1999). ?Double-blind treatment of major depression with dehydroepiandrosterone?. The American Journal of Psychiatry 156 (4): 646?9. PMID 10200751.
23. Schmidt, P. J.; Daly, R. C.; Bloch, M. et al. (2005). ?Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression?. Arch. Gen. Psychiatry 62 (2): 154?62. doi:10.1001/ archpsyc.62.2.154. PMID 15699292.
24. Kawano, H.; Yasue, H.; Kitagawa, A. et al. (2003). ?Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men?. J. Clin. Endocrinol. Metab. 88 (7): 3190?5. doi:10.1210/jc.2002-021603. PMID 12843164.
25. Nair, K. S.; Rizza, R. A.; O?Brien, P. et al. (2006). ?DHEA in elderly women and DHEA or testosterone in elderly men?. N. Engl. J. Med. 355 (16): 1647?59. doi:10.1056/NEJMoa054629. PMID 17050889.
26. Alhaj et al., Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a doubleblind, placebo-controlled study, Psychopharmacology (2006) 188: 541?551
27. Wallace, M. B.; Lim, J.; Cutler, A.; Bucci, L. (1999). ?Effects of dehydroepiandrosterone vs androstenedione supplementation in men?. Medicine and Science in Sports and Exercise 31 (12): 1788?92. doi:10.1097/00005768-199912000- 00014. PMID 10613429.
28. Barrett-Connor, E.; Khaw, K. T.; Yen, S. S. (1986). ?A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease?. N. Engl. J. Med. 315 (24): 1519?24. PMID 2946952.
29. Boggs, Will. ?DHEA Restores Oxidative Balance in Type 2 Diabetes?. Medscape. http://www.medscape.com/viewarticle/ 567316. Retrieved on 2007-12-14.
30. Schulz, S.; Klann, R. C.; Sch?nfeld, S.; Nyce, J. W. (1992). ?Mechanisms of cell growth inhibition and cell cycle arrest in human colonic adenocarcinoma cells by dehydroepiandrosterone: role of isoprenoid biosynthesis?. Cancer Res. 52 (5): 1372?6. PMID 1531325.
31. Loria, R. M. (2002). ?Immune up-regulation and tumor apoptosis by androstene steroids?. Steroids 67 (12): 953?66. doi:10.1016/S0039-128X(02)00043-0. PMID 12398992.
32. Fukui, M.; Kitagawa, Y.; Nakamura, N.; Kadono, M.; Yoshida, M.; Hirata, C.; Wada, K.; Hasegawa, G.; Yoshikawa, T. (2005). ?Serum dehydroepiandrosterone sulfate concentration and carotid atherosclerosis in men with type 2 diabetes?. Atherosclerosis Volume 181 (2): 339?344. doi:10.1016/j.atherosclerosis. 2005.01.014.
33. Martina, V.; Benso, A.; Gigliardi, V. R. et al. (2006). ?Short-term dehydroepiandrosterone tereatment increases platelet cGMP production in elderly male subjects?. Clin. Endocrinol. (Oxf.) 11 (March;64(3)): 260?4. doi:10.1111/ j.1365-2265.2006.02454.x.
34. Enomoto, Mika (2008). ?Serum Dehydroepiandrosterone Sulfate Levels Predict Longevity in Men: 27-Year Follow-Up Study in a Community-Based Cohort (Tanushimaru Study).?. Journal of the American Geriatrics Society 56 (6): 994. doi: 10.1111/j.1532-5415.2008.01692.x.
35. October in Stroke, Medicare records on more than 150,000 people hospitalized for stroke in nine U.S. cities found that an increase in air pollution from the lowest to the highest concentrations was associated with a 1.03 percent increase in incidence.
36 . According to the EPA, Fine-particle pollution causes an estimated 20,000 premature deaths in the United States each year. Further, emissions of nitrogen oxide and sulfur dioxide from pots form smog and soot and are linked to thousands of premature deaths and illnesses every year.
37 . European Commission, some 9,000 deaths in the UK are caused or hastened by air pollution.
38. Women who live in areas with greater air pollution have a higher susceptibility of developing and dying from coronary heart disease (CHD), according to a multi-decade study accepted today for publication in the peer-reviewed journal Environmental Health Perspectives (EHP). When ozone combines with particulate matter (PM), women?s risk of fatal CHD can increase up to twofold.
39. Hauffa BP et al 1984
40. Valenti G 2002;
41. Valenti G et al 2004.
42. 30-Nafziger AN et al 1998
43. 31- Pavlov EP et al 1986.